The  ||| S:0 E:4 ||| DT
RNA-binding  ||| S:4 E:16 ||| JJ
protein  ||| S:16 E:24 ||| NN
LARP1  ||| S:24 E:30 ||| NN
is  ||| S:30 E:33 ||| VBZ
a  ||| S:33 E:35 ||| DT
post-transcriptional  ||| S:35 E:56 ||| JJ
regulator  ||| S:56 E:66 ||| NN
of  ||| S:66 E:69 ||| IN
survival  ||| S:69 E:78 ||| NN
and  ||| S:78 E:82 ||| CC
tumorigenesis  ||| S:82 E:96 ||| NN
in  ||| S:96 E:99 ||| IN
ovarian  ||| S:99 E:107 ||| JJ
cancer  ||| S:107 E:114 ||| NN
RNA-binding  ||| S:114 E:126 ||| JJ
proteins  ||| S:126 E:135 ||| NNS
( ||| S:135 E:136 ||| -LRB-
RBPs ||| S:136 E:140 ||| NNP
)  ||| S:140 E:142 ||| -RRB-
are  ||| S:142 E:146 ||| VBP
increasingly  ||| S:146 E:159 ||| RB
identified  ||| S:159 E:170 ||| VBN
as  ||| S:170 E:173 ||| IN
post-transcriptional  ||| S:173 E:194 ||| JJ
drivers  ||| S:194 E:202 ||| NNS
of  ||| S:202 E:205 ||| IN
cancer  ||| S:205 E:212 ||| NN
progression ||| S:212 E:223 ||| NN
.  ||| S:223 E:225 ||| .
The  ||| S:225 E:229 ||| DT
RBP  ||| S:229 E:233 ||| NNP
LARP1  ||| S:233 E:239 ||| NNP
is  ||| S:239 E:242 ||| VBZ
an  ||| S:242 E:245 ||| DT
mRNA  ||| S:245 E:250 ||| JJ
stability  ||| S:250 E:260 ||| NN
regulator ||| S:260 E:269 ||| NN
,  ||| S:269 E:271 ||| ,
and  ||| S:271 E:275 ||| CC
elevated  ||| S:275 E:284 ||| JJ
expression  ||| S:284 E:295 ||| NN
of  ||| S:295 E:298 ||| IN
the  ||| S:298 E:302 ||| DT
protein  ||| S:302 E:310 ||| NN
in  ||| S:310 E:313 ||| IN
hepatocellular  ||| S:313 E:328 ||| NN
and  ||| S:328 E:332 ||| CC
lung  ||| S:332 E:337 ||| NN
cancers  ||| S:337 E:345 ||| NNS
is  ||| S:345 E:348 ||| VBZ
correlated  ||| S:348 E:359 ||| VBN
with  ||| S:359 E:364 ||| IN
adverse  ||| S:364 E:372 ||| JJ
prognosis ||| S:372 E:381 ||| NN
.  ||| S:381 E:383 ||| .
LARP1  ||| S:383 E:389 ||| NNP
associates  ||| S:389 E:400 ||| NNS
with  ||| S:400 E:405 ||| IN
an  ||| S:405 E:408 ||| DT
mRNA  ||| S:408 E:413 ||| JJ
interactome  ||| S:413 E:425 ||| NN
that  ||| S:425 E:430 ||| WDT
is  ||| S:430 E:433 ||| VBZ
enriched  ||| S:433 E:442 ||| VBN
for  ||| S:442 E:446 ||| IN
oncogenic  ||| S:446 E:456 ||| JJ
transcripts ||| S:456 E:467 ||| NNS
.  ||| S:467 E:469 ||| .
Here  ||| S:469 E:474 ||| RB
we  ||| S:474 E:477 ||| PRP
explore  ||| S:477 E:485 ||| VB
the  ||| S:485 E:489 ||| DT
role  ||| S:489 E:494 ||| NN
of  ||| S:494 E:497 ||| IN
LARP1  ||| S:497 E:503 ||| CD
in  ||| S:503 E:506 ||| IN
epithelial  ||| S:506 E:517 ||| JJ
ovarian  ||| S:517 E:525 ||| JJ
cancer ||| S:525 E:531 ||| NN
,  ||| S:531 E:533 ||| ,
a  ||| S:533 E:535 ||| DT
disease  ||| S:535 E:543 ||| NN
characterized  ||| S:543 E:557 ||| VBN
by  ||| S:557 E:560 ||| IN
the  ||| S:560 E:564 ||| DT
rapid  ||| S:564 E:570 ||| JJ
acquisition  ||| S:570 E:582 ||| NN
of  ||| S:582 E:585 ||| IN
resistance  ||| S:585 E:596 ||| NN
to  ||| S:596 E:599 ||| TO
chemotherapy  ||| S:599 E:612 ||| VB
through  ||| S:612 E:620 ||| IN
the  ||| S:620 E:624 ||| DT
induction  ||| S:624 E:634 ||| NN
of  ||| S:634 E:637 ||| IN
pro-survival  ||| S:637 E:650 ||| JJ
signalling ||| S:650 E:660 ||| NN
.  ||| S:660 E:662 ||| .
We  ||| S:662 E:665 ||| PRP
show ||| S:665 E:669 ||| VBP
,  ||| S:669 E:671 ||| ,
using  ||| S:671 E:677 ||| VBG
ovarian  ||| S:677 E:685 ||| JJ
cell  ||| S:685 E:690 ||| NN
lines  ||| S:690 E:696 ||| NNS
and  ||| S:696 E:700 ||| CC
xenografts ||| S:700 E:710 ||| NN
,  ||| S:710 E:712 ||| ,
that  ||| S:712 E:717 ||| IN
LARP1  ||| S:717 E:723 ||| NNP
is  ||| S:723 E:726 ||| VBZ
required  ||| S:726 E:735 ||| VBN
for  ||| S:735 E:739 ||| IN
cancer  ||| S:739 E:746 ||| NN
cell  ||| S:746 E:751 ||| NN
survival  ||| S:751 E:760 ||| NN
and  ||| S:760 E:764 ||| CC
chemotherapy  ||| S:764 E:777 ||| JJ
resistance ||| S:777 E:787 ||| NN
.  ||| S:787 E:789 ||| .
LARP1  ||| S:789 E:795 ||| NNP
promotes  ||| S:795 E:804 ||| VBZ
tumour  ||| S:804 E:811 ||| JJ
formation  ||| S:811 E:821 ||| NN
in  ||| S:821 E:824 ||| IN
vivo  ||| S:824 E:829 ||| NN
and  ||| S:829 E:833 ||| CC
maintains  ||| S:833 E:843 ||| JJ
cancer  ||| S:843 E:850 ||| NN
stem  ||| S:850 E:855 ||| VBP
cell-like  ||| S:855 E:865 ||| JJ
populations ||| S:865 E:876 ||| NNS
.  ||| S:876 E:878 ||| .
Using  ||| S:878 E:884 ||| VBG
transcriptomic  ||| S:884 E:899 ||| JJ
analysis  ||| S:899 E:908 ||| NN
following  ||| S:908 E:918 ||| VBG
LARP1  ||| S:918 E:924 ||| CD
knockdown ||| S:924 E:933 ||| NN
,  ||| S:933 E:935 ||| ,
cross-referenced  ||| S:935 E:952 ||| JJ
against  ||| S:952 E:960 ||| IN
the  ||| S:960 E:964 ||| DT
LARP1  ||| S:964 E:970 ||| JJ
interactome ||| S:970 E:981 ||| NN
,  ||| S:981 E:983 ||| ,
we  ||| S:983 E:986 ||| PRP
identify  ||| S:986 E:995 ||| VBP
BCL2  ||| S:995 E:1000 ||| NNP
and  ||| S:1000 E:1004 ||| CC
BIK  ||| S:1004 E:1008 ||| NNP
as  ||| S:1008 E:1011 ||| IN
LARP1  ||| S:1011 E:1017 ||| CD
mRNA  ||| S:1017 E:1022 ||| JJ
targets ||| S:1022 E:1029 ||| NNS
.  ||| S:1029 E:1031 ||| .
We  ||| S:1031 E:1034 ||| PRP
demonstrate  ||| S:1034 E:1046 ||| VBP
that ||| S:1046 E:1050 ||| RB
,  ||| S:1050 E:1052 ||| ,
through  ||| S:1052 E:1060 ||| IN
an  ||| S:1060 E:1063 ||| DT
interaction  ||| S:1063 E:1075 ||| NN
with  ||| S:1075 E:1080 ||| IN
the  ||| S:1080 E:1084 ||| DT
3 ||| S:1084 E:1085 ||| CD
'  ||| S:1085 E:1087 ||| POS
untranslated  ||| S:1087 E:1100 ||| JJ
regions  ||| S:1100 E:1108 ||| NNS
( ||| S:1108 E:1109 ||| -LRB-
3 ||| S:1109 E:1110 ||| NNP
'  ||| S:1110 E:1112 ||| POS
UTRs ||| S:1112 E:1116 ||| JJ
)  ||| S:1116 E:1118 ||| -RRB-
of  ||| S:1118 E:1121 ||| IN
BCL2  ||| S:1121 E:1126 ||| NNP
and  ||| S:1126 E:1130 ||| CC
BIK ||| S:1130 E:1133 ||| NNP
,  ||| S:1133 E:1135 ||| ,
LARP1  ||| S:1135 E:1141 ||| NNP
stabilizes  ||| S:1141 E:1152 ||| VBZ
BCL2  ||| S:1152 E:1157 ||| NNP
but  ||| S:1157 E:1161 ||| CC
destabilizes  ||| S:1161 E:1174 ||| JJ
BIK  ||| S:1174 E:1178 ||| NN
with  ||| S:1178 E:1183 ||| IN
the  ||| S:1183 E:1187 ||| DT
net  ||| S:1187 E:1191 ||| JJ
effect  ||| S:1191 E:1198 ||| NN
of  ||| S:1198 E:1201 ||| IN
resisting  ||| S:1201 E:1211 ||| VBG
apoptosis ||| S:1211 E:1220 ||| NNS
.  ||| S:1220 E:1222 ||| .
Together ||| S:1222 E:1230 ||| RB
,  ||| S:1230 E:1232 ||| ,
our  ||| S:1232 E:1236 ||| PRP$
data  ||| S:1236 E:1241 ||| NNS
indicate  ||| S:1241 E:1250 ||| VBP
that  ||| S:1250 E:1255 ||| IN
by  ||| S:1255 E:1258 ||| IN
differentially  ||| S:1258 E:1273 ||| NNS
regulating  ||| S:1273 E:1284 ||| VBG
the  ||| S:1284 E:1288 ||| DT
stability  ||| S:1288 E:1298 ||| NN
of  ||| S:1298 E:1301 ||| IN
a  ||| S:1301 E:1303 ||| DT
selection  ||| S:1303 E:1313 ||| NN
of  ||| S:1313 E:1316 ||| IN
mRNAs ||| S:1316 E:1321 ||| NNP
,  ||| S:1321 E:1323 ||| ,
LARP1  ||| S:1323 E:1329 ||| NNP
promotes  ||| S:1329 E:1338 ||| VBZ
ovarian  ||| S:1338 E:1346 ||| JJ
cancer  ||| S:1346 E:1353 ||| NN
progression  ||| S:1353 E:1365 ||| NNS
and  ||| S:1365 E:1369 ||| CC
chemotherapy  ||| S:1369 E:1382 ||| JJ
resistance ||| S:1382 E:1392 ||| NN
.  ||| S:1392 E:1394 ||| .
